Serum Complement in the Newborn: An Investigation of Complement Activity in Normal Infants and in Rh and AB Hemolytic Disease*

Ewald, Roger A.; Williams, Jon L.; Bowden, D. H.

doi:10.1111/j.1423-0410.1961.tb03168.x

Cited by 22 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study indicates that no consumption of complement occurs in hemolytic disease of the newborn, in agreement with the observa tion of E w a l d et al [18] who reported normal CH50 levels in infants with AB hemolytic disease and above normal levels in infants with Rh hemolytic disease. These authors could not correlate CHJ0 levels with antibody titers, bilirubin levels, or severity in ABO hemolytic disease of the newborn.…”

Section: Discussionsupporting

confidence: 81%

Developmental Aspects of the Human Complement System

et al. 1971

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 81%

Developmental Aspects of the Human Complement System

et al. 1971

View full text Add to dashboard Cite

“…A hemolytic assay measuring the kinetics of lysis (17,18) was performed to evaluate AP lytic activity. This method is based on the determination of the time required for serum to lyse 50% of an erythrocyte suspension (t 1/2 ) under standard conditions.…”

Section: Methodsmentioning

confidence: 99%

Alternative complement pathway and factor B activities in rats with altered blood levels of thyroid hormone

Bitencourt

Duarte

Azzolini

et al. 2012

Braz J Med Biol Res

View full text Add to dashboard Cite

Evaluating the activity of the complement system under conditions of altered thyroid hormone levels might help elucidate the role of complement in triggering autoimmune processes. Here, we investigated alternative pathway (AP) activity in male Wistar rats (180 ± 10 g) after altering their thyroid hormone levels by treatment with triiodothyronine (T3), propylthiouracil (PTU) or thyroidectomy. T3 and thyroxine (T4) levels were determined by chemiluminescence assays. Hemolytic assays were performed to evaluate the lytic activity of the AP. Factor B activity was evaluated using factor B-deficient serum. An anti-human factor B antibody was used to measure factor B levels in serum by radial immunodiffusion. T3 measurements in thyroidectomized animals or animals treated with PTU demonstrated a significant reduction in hormone levels compared to control. The results showed a reduction in AP lytic activity in rats treated with increasing amounts of T3 (1, 10, or 50 µg). Factor B activity was also decreased in the sera of hyperthyroid rats treated with 1 to 50 µg T3. Additionally, treating rats with 25 µg T3 significantly increased factor B levels in their sera (P < 0.01). In contrast, increased factor B concentration and activity (32%) were observed in hypothyroid rats. We conclude that alterations in thyroid hormone levels affect the activity of the AP and factor B, which may in turn affect the roles of AP and factor B in antibody production.

show abstract

“…

Only a few papers have been published, dealing with the immunological reactivity after exchange transfusion (ET). Complement values have been studied b y EWALD et al [7, 291. EWALD reports, that complement values in newborn with rh incompatibility, during the first few days of life, were either the same or even higher than in normal infants.

…”

mentioning

confidence: 99%